Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity

Università degli Studi dell'Insubria

Overview

Despite the great number of reports about the efficacy of oestrogens or antimuscarinics on OAB symptoms, so far no author has tried to investigate whether the concomitant administration of these two drugs, acting on two different pathophysiological mechanisms, could have a synergic effect reducing the rate of non-responders to treatment.

Study Type

INTERVENTIONAL

Conditions

Overactive Bladder

Interventions

Tolterodine 4 mgDRUG

arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeksDRUG

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * All post-menopausal women with symptoms of overactive bladder and urodynamically proven pure detrusor overactivity Exclusion Criteria: * concomitant urodynamic stress incontinence * documented recurrent urinary tract infections * previous antimuscarinic treatment * previous pelvic surgery * concomitant systemic HRT * history of breast or endometrial cancer * neurological disease * clinical contraindications to treatment with oestrogen or antimuscarinics * patients included in other ongoing clinical trials

Locations (1)

Department of Gynecology and Obstetrics - Università dell'Insubria

Varese, Italy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.